Capstone Holding Corp. · NASDAQ:CAPS
Capstone — Capstone Therapeutics — Corporate Update (November 2013)
16 slides from Capstone's corporate update, Nov 21, 2013
Slide 1: Capstone Therapeutics Operating Update
Capstone Therapeutics Operating Update November 21, 2013
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements in this presentation or otherwise attributable to Capstone regarding our business that are not historical facts are forward looking statements made pursuant to the safe harbor that could cause actual results to differ materially from predicted results. These risks in
Slide 3: Cash Report
Cash Report Cash Use and Ending Balance 30Q2013 CAPS $ (381,000) Lipimetix § (559,000) Consolidated $ (940,000) Cash Balance $ 7,183,000 Note: Cash Balance at September 30, 2013 includes LipimetixX Development, LLC
Slide 4: Qui Tam Lawsuit Update
Qui Tam Lawsuit Update @ Next discovery hearing to be held in December 2013 — duration of discovery process uncertain @ Proposed DOJ/Orthofix settlement accepted by court - had slowed lawsuit progress @ DOJ/US Government has not joined complaint against CAPS @ Settlement/Trial: Timing Unknown
Slide 5: LipimetiX Development LLC (JV)
LipimetiX Development LLC (JV) @ CAPS contributed 26M tr 60% (ownership) @ 2 tranche funding str @ S5M of CAPS cont bution hes preferential distribution right 5 Tpit LLC baa contributed UAB license for current/future IP, 40% (ownersh ca V one Dennis Goldberg, Ph.D. and team to manage program be nu B
Slide 6: AEM-28 Rational Design at UAB
AEM-28 Rational Design at UAB "Hinge region’ - 299 aa down to 28 aa with full function ‘ Apolipoprotein E ¢ A t noire @» € Receptor binding region -LRKLRKRLLR DWLKAFYDKVAEKLKAEF AEM-28
Slide 7: Target Indications
Target Indications @ Homozygous Familial Hypercholesterolemia (HoFH) > Absence of LDL receptor function > Cannot clear LDL or control cholesterol levels > Orphan indication, potential for rapid development/ approval > Potential $200 million market @ Severe Refractory Hypercholesterolemia > Not respo
Slide 8: Target Indications (cont'd)
Target Indications (cont’d) @ Acute Coronary Syndrome > 1,300,000 hospitalizations/year in US alone > 10-25% recurrence rate in first year after event > Reduce atherosclerosis burden and mortality > Potential $11 Billion annual market > Will require an outcome study and funding by big Pharma SS CAPS
Slide 9: Homozygous FH Animal Evidence
Homozygous FH Animal Evidence: AEM -28 Reduces LDL & VLDL human FH patients > WHHL rabbi ins, bil ate «led MDL chal 1 t 0.08 eV nection _ | Se al Foy : 3 oe Also results in = = reduction of several 8 markers of 3 Oe tL atherosclerosis = 0.02 oO a 0.00 + , 6 10 25 30 Elution volume (mL) Gupta, et al.
Slide 10: ACS Animal Evidence
ACS Animal Evidence: Direct Artery Wall Effects Reduce Atherosclerosis Reduction in Atherosclerosis far Exceeds Cholesterol Drop Control Animal Plasma Cholesterol = 1600 mg/dl ¢ y fatty streaks AEM-28 Animal Plasma Cholesterol = 1100 mg/dl @8% of 14 streaks
Slide 11: AEM-28 Sustained Effect on Atherosclerotic Lesions in Fat-fed APO E Null Mice
AEM-28 Sustained Effect on Atherosclerotic Lesions in Fat-fed APO E Null Mice 4 Weeks After Stopping Drug Treatment En face Lesion Area (n=13 in each group) Representative en face Lesions Control ‘oster P| ti Full Poster available at aN CAPSTONE
Slide 12: Summary — Apo E Mimetics
Summary — Apo E Mimetics @ Novel mimetics of key lipid/cholesterol metabolism protein > Utilizes alternate receptors on liver to clear atherogenic lipoproteins > Induces direct anti-inflammatory and lesion regression effects on artery walls > Believed to be only product in development with both effe
Slide 13: LipimetiX Operating Update
LIBIMEU Operating Update 2012 N EM Pre-IND meeting letter filed with FDA FDA for Hypercholesterolemi Preclinical Toxicity staales initiated / eontinuing oO 900 o Schedule: > FDA IND submission to follow scheduling with Canadian CRO udget: > Total Program Cost still = $6M to complete 27-
Slide 14: AEM-28 Human Protocol Summary
AEM-28 Human Protocol Summary @ Phase 1a > Objectiv: e Safety onda lerability Evaluate Pharmacokinetics > Format: ® Phase = me > Obje . Stay a Tolerability Evaluate eee L, LDL > Format: SS CAPSTONE
Slide 15: Capstone Summary
Capstone Summary @ Two Programs: > Apo E Mimetic Peptide AEM-28 in LDL Reduction > AZX100 in Pulmonary Fibrosis — LRRI Results pr ‘a @ Continue CAPS Virtual Operation (1.5 Employees/ Consultants) to Preserve Cash @ Cash Resources Believed to be Adequate to Reach Value Milestones eZ CAPSTONE
Slide 16: Capstone Therapeutics
~~ CAPSTONE THERAPEUTIC OTCQB: CAPS www, caanneaahis com pstone Therapeutics 1275 West ashintn Steet Suite 104 ve 02) 206-6820. SS CAPSTONE ie
Capstone Therapeutics — Corporate Update (November 2013) on 6ix